Merck, Inc.
🇺🇸United States
A Study in Subjects With Retinal Detachment
Phase 1
Completed
- Conditions
- Retinal Detachment
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT00210067
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
Not Applicable
Completed
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT00211601
Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)
Phase 4
Withdrawn
- Conditions
- Pyoderma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00202891
A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00202852
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
Phase 3
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: PlaceboBiological: infliximab
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 76
- Registration Number
- NCT00202865
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT00202839
V260 Registration Study (V260-013)(COMPLETED)
Phase 3
Completed
- Conditions
- Rotavirus
- Interventions
- Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT00166517
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 357
- Registration Number
- NCT00160251
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
Phase 4
Completed
- Conditions
- Complicated Intra-abdominal Infection
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 134
- Registration Number
- NCT00157898
A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00157872
© Copyright 2025. All Rights Reserved by MedPath